Pain Research and Management
Volume 2019 (2019), Article ID 9675654, 8 pages
https://doi.org/10.1155/2019/9675654

Research Article

Characteristics of Chronic Pain among Head and Neck Cancer Patients Treated with Radiation Therapy: A Retrospective Study

Anusha Kallurkar,¹ Shreedhar Kulkarni,² Kristin Delfino,³ Daniel Ferraro,⁴ and Krishna Rao⁵

¹Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, USA
²Division of Medicine/Psychiatry, Department of Medicine, SIU School of Medicine, Springfield, IL, USA
³Department of Surgery, SIU School of Medicine, Springfield, IL, USA
⁴University Radiologists, Memorial Medical Center, Springfield, IL, USA
⁵Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine, Springfield, IL, USA

Correspondence should be addressed to Shreedhar Kulkarni; shree.kulkarni82@gmail.com

Received 19 November 2018; Revised 14 March 2019; Accepted 27 March 2019; Published 6 May 2019

Academic Editor: Federica Galli

Copyright © 2019 Anusha Kallurkar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Pain is common among patients with head and neck cancer (HNC). However, there are very limited data on chronic pain among HNC patients treated with radiation therapy (XRT). In this retrospective study, we focused on the characteristics of chronic post-XRT pain in such patients. Post-XRT pain is common among HNC patients; however, we found discrepancy between frequency of treatment and frequency of chronic pain, suggesting poor documentation of pain in the medical records. Among patients who reported to have chronic post-XRT pain, most of them described having severe pain and used descriptors of neuropathic pain. Pharynx was the commonest site of cancer as well as the commonest site of cancer-related chronic pain; squamous cell carcinoma was the most frequent histological pattern, and opioids were used most often to treat such chronic pain. There was a significant association between chronic pain and number of sites of pain, and chronic pain was also associated with use of opioids.

1. Introduction

Pain is common among patients with head and neck cancer (HNC) prior to treatment and may be attributed to the cancer and/or cancer treatment. Pain in HNC patients could be due to tissue damage from several mechanisms such as mucosal injury, nerve compression, and invasion of the tumor into adjacent tissue structures with inflammation or ischemia [1]. Management of HNC includes stage-dependent single or multimodality approaches comprising surgery, chemotherapy, and/or radiation therapy (XRT). Postoperative pain can be due to tissue injury with muscle spasm and nerve injury leading to a combination of inflammatory and neuropathic components [2]. Chemotherapy-induced peripheral neuropathic pain is common and can be due to a combination of mitochondrial dysfunction, changes in expression of various cytokines, and abnormal spontaneous discharge in A and C fibers [3]. XRT can induce oral mucositis in patients with HNC and can cause oral pain due to impaired wound healing [4]. Thus, all of these modalities of treatment can cause acute pain, which often resolves within the critical three-month time span after treatment.

HNC can take up to 3 months to disappear histologically after completion of treatment, thus indicating remission of disease [5]. The follow-up visit at 3 months of completion of cancer therapy is particularly important since it helps in establishing the baseline result of treatment response and also marks the timing of the posttreatment baseline imaging [6, 7]. A negative PET-CT scan after treatment with chemoradiotherapy in HNC is associated with a high negative predictive value (>95%), and a negative scan around 3 months after completion of cancer therapy may indicate no residual disease [5, 8]. Patients who achieve a complete remission at the three-month posttreatment time point and who are still experiencing pain are thought to be having chronic pain. According to the International Association for the Study of Pain (IASP), “chronic pain” is defined as “the pain that has persisted beyond normal tissue healing time,” lasting for “more than 3 months” in the absence of other criteria [9].

Oral mucositis is a common cause of acute pain in HNC patients, and it typically lasts for 2–4 weeks after the end of radiation therapy (XRT) [10]. However, HNC patients can experience pain even up to 6–12 months after the radiation therapy [11]. There are very limited data on the prevalence and characteristics of chronic pain among HNC patients treated with XRT, and it is not clear which subgroup of HNC patients is more prone for chronic pain after XRT. In this retrospective observational study, we investigated the prevalence of chronic pain and the characteristics of patients in complete remission afflicted with chronic posttreatment pain.

2. Methods

2.1. Design

This retrospective study was conducted at Southern Illinois University (SIU) School of Medicine and Memorial Medical Center, Springfield, IL. All head and neck cancer patients aged 18 years and above, treated with radiotherapy from February 2011 to February 2016, were included in the study. Head and neck cancer patients treated only with chemotherapy were excluded. The chart review identified a total of 53 patients, who met the inclusion criteria. Demographic features such as age at diagnosis, gender and race, clinicopathologic features (location, histology, and staging of the cancer), cancer therapy (surgery and chemotherapy) and details pertinent to XRT (such as dose, duration, and area involved) were collected. In terms of location, data pertaining to upper aerodigestive tract sites (oral cavity, pharynx, larynx, nasal cavity, and paranasal sinuses) as well as salivary glands were collected. We focused on cancers of the oral cavity, pharynx, and larynx in this study because of their similarities in epidemiology, treatment, and prognosis; cancers of the lip, salivary gland, nose, paranasal sinuses, middle ear, nerves and bones, thyroid, nonmelanoma skin cancers, lymphoma, and sarcomas were excluded.

Data were also collected regarding the characteristics of pain: location, onset, frequency, severity, nature of pain, and information regarding use of medications including opioids, gabapentin, TCAs, and NSAIDs. Data regarding characteristics of pain up to 3 months after completion of XRT were categorized as “data related to acute pain,” and subsequent data (after 3 months of completion of XRT) were considered as “data related to chronic pain.” Pain was documented as mild, moderate, or severe based on the documentation in the charts. If pain severity was documented numerically, it was converted into mild (documented as 1–3 in the charts), moderate [4–6], and severe [7–10]. The local institutional review board approved the study, protocol number 17-021 (approval date 02/20/2017).

2.2. Statistical Analyses

Data were analyzed with the use of SAS software, version 9.4, and Zotero bibliography software was used for citing references. Descriptive statistics were computed for all study variables. Continuous variables are described with measures of central tendency (mean and median) and dispersion (range and standard deviation). Categorical variables are summarized as frequencies and percentages. Given smaller cell sizes, the following adaptations were made during statistical analyses: cancer stages were grouped into “stage 1 or 2” and “stage 3 or 4”; data for mild, moderate, and severe pain were combined into one group, and number of sites of pain were grouped into three categories such as “pain at 0 site,” “pain at 1 site,” and “pain at 2 + sites.” Statistical analysis was not performed for use of TCA’s given smaller sample size. Fisher’s exact tests were used to compare categorical variables. Independent t-tests (or nonparametric equivalent) were used to compare continuous variables. All significance was assumed at the level.

3. Results

Demographic and clinicopathologic factors are described in Tables 1 (categorical variables) and 2 (continuous variables). Mean age at diagnosis was 61.23 years, and 73.6% were males. 88.7% of the patients had squamous cell carcinoma (n = 47), and other types of histology included adenocarcinoma (n = 1), high-grade neuroendocrine tumor (n = 1), solitary extramedullary plasmacytoma (n = 1), and adenoid cystic carcinoma (n = 1).

Table 1: Demographic and clinicopathologic factors (categorical variables) (frequency and percentage of demographic factors including age, gender, and race and clinicopathologic factors such as histology, cancer staging, severity of pain, and cancer treatment).

Variable
n
%

Categorical variables

Gender
Female
14
26.4

Male
39
73.6

Race
White
46
86.8

AA
5
9.4

Histology
Squamous
47
88.7

Staging
1
4
7.6

2
4
7.6

3
5
9.4

4
21
39.6

Surgery
No
32
60.4

Yes
21
39.6

Chemo
No
21
39.6

Yes
32
60.4

Severity of chronic pain
No pain
35
66.0

Mild
1
1.9

Moderate
4
7.5

Severe
13
24.5

Medication

Use of opioids
No
20
37.7

Yes
33
62.3

Use of gabapentin
No
45
84.9

Yes
8
15.1

Use of TCAs for chronic pain
No
47
88.7

Yes
6
11.3

Use of NSAIDs
No
39
73.6

Yes
14
26.4

Table 2: Demographic and clinicopathologic factors (continuous variables).

Variable
n
Mean
Std. error
Median
Std. dev.
Min.
Max.

Age at diagnosis
53
61.23
1.73
59.00
12.62
40.00
91.00

XRT dose
53
6063.34
201.30
6600.00
1465.47
600.00
7000.00

XRT duration
53
43.04
1.77
45.00
12.85
4.00
75.00

Number of sites of pain
53.00
1.21
0.19
1.00
1.38
0.00
6.00

A total of 41 patients (77.4%) reported any kind of treatment for chronic pain, whereas only 32 patients (60.38%) reported any kind of chronic pain, suggesting poor documentation of pain characteristics in the charts. There was insufficient description of nature of pain; among the patients who reported any kind of chronic pain (n = 32), only 4 individuals described the nature of their pain (all of them used descriptors of neuropathic pain such as stinging or burning pain) and less than 4 individuals reported onset, frequency of chronic pain, and exacerbating features. Eleven patients died during the study period with average duration of survival of 15 months.

Pharynx (Table 3) was the most common location of cancer (39.6%), and oropharynx was the most frequent subsite of HNC (34%). Site of cancer was associated with use of medications. Specifically, laryngeal cancer (; supraglottic cancer, ) was associated with higher use of gabapentin, and cancer of pharynx (; cancer of oropharynx, ) was associated with lower use of gabapentin.

Table 3: Site of cancer: frequency and percentage of prevalence of cancer by site and subsites and association between site of cancer and use of medications.

Site of cancer
Total
Use of opioids
Use of NSAIDs
Use of gabapentin

n
%
% yes

% yes

% yes

1. Oral cavity
No
47
88.7
61.7
1
25.5
0.649
12.8
0.219

Yes
6
11.3
66.7
33.3
33.3

1A. Lip
No
53
100
62.3
—
26.4
—
15.1
—

Yes
0
0

1B. Buccal mucosa
No
53
100
62.3
—
26.4
—
15.1
—

Yes
0
0

1C. Alveolar ridge, retromolar trigone
No
50
94.3
62.0
1
24.0
0.167
16.0
1

Yes
3
5.7
66.7
66.7
0.0

1D. Floor of mouth
No
50
94.3
60.0
0.282
26.0
1
12.0
0.056

Yes
3
5.7
100.0
33.3
66.7

1E. Hard palate
No
52
98.1
63.5
0.377
26.9
1
15.4
1

Yes
1
1.9
0.0
0.0
0.0

1F. Oral tongue
No
51
96.2
60.8
0.521
25.5
0.462
15.7
1

Yes
2
3.8
100.0
50.0
0.0

2. Pharynx
No
32
60.4
62.5
1
31.3
0.362
25.0
0.016

Yes
21
39.6
61.9
19.0
0.0

2A. Nasopharynx
No
52
98.1
63.5
0.377
26.9
1
15.4
1

Yes
1
1.9
0.0
0.0
0.0

2B. Oropharynx
No
35
66
60.0
0.768
25.7
1
22.9
0.04

Yes
18
34
66.7
27.8
0.0

2C. Oropharynx: base of tongue
No
44
83
63.6
0.715
27.3
1
18.2
0.324

Yes
9
17
55.6
22.2
0.0

2D. Soft palate
No
49
92.5
63.3
0.627
28.6
0.563
16.3
1

Yes
4
7.5
50.0
0.0
0.0

2E. Tonsillar fossa pillar
No
43
81.1
58.1
0.286
25.6
1
18.6
0.327

Yes
10
18.9
80.0
30.0
0.0

2F. Hypopharynx, pyriform sinus
No
46
86.8
65.2
0.405
30.4
0.17
17.4
0.577

Yes
7
13.2
42.9
0.0
0.0

3. Larynx
No
36
67.9
55.6
0.225
19.4
0.109
5.6
0.01

Yes
17
32.1
76.5
41.2
35.3

3A. Supraglottis
No
44
83
56.8
0.129
27.3
1
9.1
0.021

Yes
9
17
88.9
22.2
44.4

3B. Glottis
No
46
86.8
60.9
0.697
21.7
0.07
13.0
0.283

Yes
7
13.2
71.4
57.1
28.6

3C. Subglottis
No
50
94.3
60.0
0.282
26.0
1
14.0
0.394

Yes
3
5.7
100.0
33.3
33.3

4. Nasal cavity
No
50
94.3
62.0
1
28.0
0.557
16.0
1

Yes
3
5.7
66.7
0.0
0.0

5. Paranasal sinuses
No
53
100
62.3
—
26.4
—
15.1
—

Yes
0
0

6. Others
No
50
94.3
64.0
0.549
28.0
0.557
16.0
1

Yes
3
5.7
33.3
0.0
0.0

7. Salivary gland
No
50
94.3
66.0
0.049
26.0
1
16.0
1

Yes
3
5.7
0.0
33.3
0.0

Several cell sizes are very small and have been excluded from final statistical analyses. The ones that are included in the interpretation of final results are described in bold text.

Pharynx (26.4%) was the commonest site of cancer-related chronic pain, followed by oral cavity (24.5%) (Table 4). Chronic neck pain was associated with use of gabapentin ().

Table 4: Various sites of pain among HNC patients and association between site of pain and use of medications.

Site of pain
Total
Use of opioids
Use of NSAIDs
Use of gabapentin

n
%
% yes

% yes

% yes

1. Oral cavity
No
40
75.5
55.0
0.098
27.5
1
15.0
1

Yes
13
24.5
84.6
23.1
15.4

2. Pharynx
No
39
73.6
56.4
0.203
28.2
0.735
17.9
0.665

Yes
14
26.4
78.6
21.4
7.1

3. Eyes
No
52
98.1
61.5
1
26.9
1
15.4
1

Yes
1
1.9
100.0
0.0
0.0

4. Nasal cavity, paranasal sinuses
No
52
98.1
61.5
1
26.9
1
15.4
1

Yes
1
1.9
100.0
0.0
0.0

5. Odynophagia
No
44
83
59.1
0.456
25.0
0.684
13.6
0.611

Yes
9
17
77.8
33.3
22.2

6. Headache
No
50
94.3
60.0
0.282
24.0
0.167
14.0
0.394

Yes
3
5.7
100.0
66.7
33.3

7. Face
No
48
90.6
58.3
0.144
27.1
1
14.6
0.574

Yes
5
9.4
100.0
20.0
20.0

8. Ear
No
45
84.9
57.8
0.234
24.4
0.422
13.3
0.59

Yes
8
15.1
87.5
37.5
25.0

9. Neck
No
45
84.9
60.0
0.695
22.2
0.186
8.9
0.013

Yes
8
15.1
75.0
50.0
50.0

Several cell sizes are very small and have been excluded from final statistical analyses. The ones that are included in the interpretation of final results are described in bold text.

There was a significant association between chronic pain and number of pain sites (), and chronic pain was also associated with use of opioids () (Table 5). There was no significant association between site of cancer and site of cancer-related chronic pain. Surgery was not associated with chronic pain or use of pain medications (details of statistical analyses for surgery, chemotherapy, XRT dose, and duration have been listed as separate tables, which can be found in Tables 6–9, respectively). Similarly, chemotherapy had no effect on chronic pain or use of analgesics. XRT dose had no effect on chronic pain or use of pain medications. Likewise, XRT duration was not associated with chronic pain or use of analgesics.

Table 5: Characteristics of chronic pain.

Chronic pain
Fisher’s

Variable
No
Yes
Total
% no
% yes
value

Gender
Female
10
4
14
71.4
28.6
0.748

Male
25
14
39
64.1
35.9

Staging
Stage 1 or 2
4
4
8
50.0
50.0
0.679

Stage 3 or 4
17
9
26
65.4
34.6

Surgery
No
22
10
32
68.8
31.3
0.768

Yes
13
8
24
54.2
33.3

Chemo
No
16
5
21
76.2
23.8
0.247

Yes
19
13
32
59.4
40.6

Opioids
No
18
2
20
90.0
10.0
0.006

Yes
17
16
33
51.5
48.5

Gabapentin
No
33
12
45
73.3
26.7
0.014

Yes
2
6
8
25.0
75.0

TCA
No
32
15
47
68.1
31.9
0.397

Yes
3
3
6
50.0
50.0

NSAID
No
28
11
39
71.8
28.2
0.191

Yes
7
7
14
50.0
50.0

Number of sites of pain
0
20
1
21
95.2
4.8
<0.0001

1
11
4
15
73.3
26.7

2+
4
13
17
23.5
76.5

Variable
Chronic pain
N
Mean
Std. dev.
Std. error
t-test

Age
Pain = no
35
62.23
13.831
2.338
0.425

Pain = yes
18
59.28
9.916
2.337

Dose
Pain = no
35
5854
1562.68
264.14
0.149

Pain = yes
18
6470
1191.5
280.84

Duration
Pain = no
35
42.37
14.534
2.457
0.604

Pain = yes
18
44.33
8.957
2.111

Table 6: Surgery and medications.

Surgery
No
Yes
Total
Fisher’s value

Use of opioids

No
14
18
32
0.3859

Yes
6
15
21

Use of gabapentin

No
29
3
32
0.2403

Yes
16
5
21

Use of TCA

No
28
4
32
1

Yes
19
2
21

Use of NSAIDs

No
23
9
32
1

Yes
16
5
21

Table 7: Chemotherapy and medications.

Chemo
No
Yes
Total
Fisher’s value

Use of opioids

No
9
12
21
0.5733

Yes
11
21
32

Use of gabapentin

No
16
5
21
0.2403

Yes
29
3
32

Use of TCA

No
18
3
21
0.6711

Yes
29
3
32

Use of NSAIDs

No
13
8
21
0.2017

Yes
26
6
32

Table 8: XRT dose and medications.

n
Mean
Std. dev.
Std. error
value
Test

Opioids
No
20
5398.00
1910.38
427.17
0.05
Mann–Whitney

Yes
33
6466.58
937.33
163.17

Gabapentin
No
45
5981.80
1561.94
232.84
0.342
t-test

Yes
8
6522.00
579.23
204.79

TCA
No
47
6101.21
1422.24
207.45
0.603
t-test

Yes
6
5766.67
1899.12
775.31

NSAID
No
39
5922.69
1618.93
259.24
0.247
t-test

Yes
14
6455.14
839.43
224.35

Table 9: XRT duration and medications.

n
Mean
Std. dev.
Std. error
value
Test

Opioids
No
20
38.20
16.13
3.61
0.277
Mann–Whitney

Yes
33
45.97
9.51
1.66

Gabapentin
No
45
41.89
13.36
1.99
0.124
t-test

Yes
8
49.50
6.97
2.46

TCA
No
47
42.81
11.92
1.74
0.72
t-test

Yes
6
44.83
20.19
8.24

NSAID
No
39
42.56
13.42
2.15
0.659
t-test

Yes
14
44.36
11.47
3.07

4. Discussion

Pain is common among HNC patients and can be nociceptive, inflammatory, or neuropathic in nature. Nociceptive pain refers to the response to noxious stimuli and continues in the maintained presence of noxious stimuli [12]. Although inflammatory pain typically improves with resolution of inflammation, there is growing evidence to support that in some cases inflammatory state may resolve but a component of pain persists [13]. In an animal model, Christianson et al. showed that chronic inflammatory states may mimic neuropathic-like pain and continue to have persistent allodynia despite resolution of inflammation, and such allodynia responded only to gabapentin [14]. Pathophysiological changes in the pain pathways resulting from repetitive nociceptive stimulation lead to peripheral or central sensitization, which ultimately leads to transition of acute pain into chronic pain in susceptible individuals [15].

Pain is common among patients with HNC; acute post-XRT pain typically lasts for less than 3 months whereas chronic pain lasts for more than 3 months. Based on our clinical experience in managing post-XRT patients with HNC, we observed that chronic pain is commonly encountered; however, there are very limited data in the literature on the characteristics of chronic pain among HNC patients treated with XRT. Kuo and Williams listed 14 studies investigating pain in HNC patients, in which 3 studies reported persistence of pain up to 6–24 months, and prevalence of pain varied from 15% to 46% [16]. Only one study focused on post-XRT pain in HNC patients [11]. Recently, Srivastava et al. reported 54.7% patients reporting chronic post-XRT pain [17]. In our study, the sample size is larger, and we found almost two-thirds of patients to have some characteristics of chronic pain. The higher rate of prevalence of chronic pain in our study could be due to methodological differences as we included any documentation pertaining to chronic pain (location, nature, frequency of pain, etc.) in the study analysis.

We found discrepancy between frequency of treatment and frequency of chronic pain suggesting poor documentation of pain in the medical records, and less than 4 individuals reported onset (n = 1), frequency (n = 3), and exacerbating factors (n = 2) of chronic pain. It is difficult to generalize these data, given small proportion of patients receiving appropriate documentation. Nevertheless, this phenomenon of inadequate pain documentation is not limited to patients with HNC. Fink [18] reported poor documentation of acute and chronic noncancer pain. However, appropriate cancer pain documentation is one of the key elements of the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI), and Ranpura et al. showed improvement in documentation of pain among cancer patients with orientation and education of healthcare providers [19].

Mean age at diagnosis in our group was 61.23 years [20], and almost three-fourths of the patients were males (n = 39), which is comparable to other studies in the literature [21]. However, we found that most of our patients were Caucasians (n = 46, 86.8%) although historically, HNC is more common in African American individuals; this statistic probably reflects local demographics of Central Illinois. According to a population survey in 2013 [22], average Caucasian population in this area is 90.45%. Also, HPV-positive cases of HNC are more common in Caucasians, and we did not assess for HPV status in our study.

Among 53 patients in our study, pharynx was the most common site (39.6%), followed by larynx (32.1%), and among subsites of larynx, supraglottic carcinoma (17%) was the most common site that is consistent with the previous literature [23, 24]. In our study, laryngeal cancer (supraglottic cancer in particular) was associated with higher use of gabapentin. Supraglottic cancers usually have worse prognosis, given high frequency of cervical lymph node involvement, recurrences, and visceral metastases, likely explaining the increased use of analgesics.

Site of chronic pain was also associated with use of medications; chronic neck pain was associated with higher use of gabapentin. HNC patients treated with XRT are found to have neuropathic pain [25], and gabapentin is well established to be effective in treating neuropathic pain and seems to be promising in reducing the need for higher doses of opioids [26]. Gabapentin and opioids are commonly prescribed for pain, the likelihood of coprescription is high, and gabapentin appears to potentiate the effect of opioids [27].

There was a significant association between chronic pain and number of pain sites, and individuals with chronic pain were more likely to be treated with opioids. Murphy et al. found increased pain in HNC population to be associated with increased use of opioids [28]. Epstein et al. showed HNC patients treated with XRT to have both nociceptive and neuropathic pain despite ongoing pain management during XRT [25]. Chronic pain has been attributed to radiation therapy among patients with other cancers such as cervical cancer and breast cancer [29–31]. Several explanations are possible, explaining the chronic nature of pain among HNC patients treated with XRT. It could be related to chronic neuropathic pain or secondary to radiation-induced fibrosis as well as due to effects of XRT on the lymphatic system. Peuckmann et al. found almost half of the patients with chronic in pain breast cancer patients to have paresthesia of the skin corresponding to the areas of surgery and XRT [31]. Allodynia was associated with XRT only. Another mechanism could be that the irradiated tissue developing increased vascular permeability which in turn leads to fibrin deposition, subsequent collagen formation, and fibrosis. Such radiation-induced fibrosis could damage peripheral nerves which could lead to chronic neuropathic pain [32–34]. Thus, it is possible that such neuropathic pain secondary to XRT might be contributing to chronic pain among HNC patients treated with XRT. XRT could cause somatic pain related to osteonecrosis of bone, and it could also disrupt lymphatics, causing lymphedema and chronic swelling and likely inflammatory pain [35]. However, further research is needed in this field with prospective studies evaluating nature of chronic pain and risk factors among HNC patients treated with XRT.

Higher doses of XRT are known to have a positive correlation with chronic pain among HNC patients, possibly related to radiation-induced fibroatrophic processes [36]. However, we did not find any significant association of XRT dose or XRT duration with chronic pain or with use of pain medications (Tables 8 and 9). This could be due to the lower than average XRT dose used in our study. The average XRT dose in our study was 6063.34 cGy, which is lower as compared to the standard regimen of 7000 cGy. The lower dose may be due to refusal of further XRT by patients due to side effects of treatment and overall poor quality of life.

In our study group, surgery was not associated with chronic pain or use of pain medications (Table 6). Similarly, chemotherapy had no effect on chronic pain or use of analgesics (Table 7). There was no difference in rates of survival among patients with chronic pain as compared to those without pain. We did not have any data on use of botulinum toxin injection in HNC patients. Type-A botulinum toxin is an analgesic and a muscle relaxant and has been used to treat pain related to neck muscle spasm and contracture in post-XRT HNC patients. Along with conventional analgesics, future studies should explore Botulinum toxin injection and other therapies as therapeutic options to treat chronic pain in post-XRT HNC patients [37, 38].

Limitations of our study include the fact that it is a retrospective single center study. Comorbid chronic medical conditions were also not adjusted during the statistical analysis. The overall sample size in our study is small, and particularly, very small cell sizes () should be interpreted with caution.

5. Conclusions

In summary, post-XRT pain among HNC patients is common not only during the acute period but also in the chronic period lasting well beyond three months after completion of XRT. We found discrepancy between frequency of treatment and frequency of chronic pain, suggesting poor documentation of pain in the medical records. Among patients who reported having chronic post-XRT pain, most of them described having severe pain and used descriptors of neuropathic pain. Pharynx was the commonest site of cancer as well as the commonest site of cancer-related chronic pain; squamous cell carcinoma was the most frequent histological pattern, and opioids were used most often to treat such chronic pain. There was a significant association between chronic pain and number of pain sites, and chronic pain was associated with use of opioids. Surgery was not associated with chronic pain or use of pain medications. Similarly, chemotherapy had no effect on chronic pain or use of analgesics. XRT dose had no effect on chronic pain or use of pain medications. Likewise, XRT duration was not associated with chronic pain or use of pain medications. There was no difference in rates of survival among patients with chronic pain as compared to those without pain. Site of cancer and site of cancer-related chronic pain were associated with use of pain medications. However, these results have to be carefully interpreted, given small sample size. Further research using prospective studies with larger samples is needed to explore the characteristics of chronic pain among HNC patients treated with XRT and parse the roles of chemotherapy and radiation.

Data Availability

The clinical data used to support the findings of the study are restricted by the Springfield Committee for Research in Human Subjects (SCRIHS) in order to protect patient privacy. Data are available from Krishna Rao for researchers who meet the criteria for access to confidential data.

Disclosure

This is an unfunded investigator-initiated project. All authors, except Dr. Kallurkar, worked for SIU School of Medicine at the time of data collection.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors gratefully acknowledge the role of Kissindra Moore, who greatly assisted us in manuscript preparation.

References

C. J. Woolf and R. J. Mannion, “Neuropathic pain: aetiology, symptoms, mechanisms, and management,” The Lancet, vol. 353, no. 9168, pp. 1959–1964, 1999.

D. Ceyhan and M. S. Gulec, “Is postoperative pain only a nociceptive pain?” Journal of the Turkish Society of Algology, vol. 22, no. 2, pp. 47–52, 2010.

H. J. Park, “Chemotherapy induced peripheral neuropathic pain,” Korean Journal of Anesthesiology, vol. 67, no. 1, pp. 4–7, 2014.

S. Kumar, “Cancer pain: a critical review of mechanism-based classification and physical therapy management in palliative care,” Indian Journal of Palliative Care, vol. 17, no. 2, p. 116, 2011.

N. J. Roland and V. Paleri, Head and Neck Cancer: Multidisciplinary Management Guidelines, ENT, London, UK, 4th edition, 2011.

A. Kawecki and R. Krajewski, “Follow-up in patients treated for head and neck cancer,” Magazine of European Medical Oncology, vol. 7, no. 2, pp. 87–91, 2014.

N. Denaro, M. C. Merlano, and E. G. Russi, “Follow-up in head and neck cancer: do more does it mean do better? A systematic review and our proposal based on our experience,” Clinical and Experimental Otorhinolaryngology, vol. 9, no. 4, pp. 287–297, 2016.

British Association of Head and Neck Oncologists, “Practice care guidance for clinicians participating in the management of head and neck cancer patients in the UK. Drawn up by a Consensus Group of Practising Clinicians,” European Journal of Surgical Oncology, vol. 27, pp. S1–S17, 2001.

H. Merskey and N. Bogduk, Classification of Chronic Pain, IASP Press, Seatle, WC, USA, 1994.

A. Mirabile, M. Airoldi, C. Ripamonti et al., “Pain management in head and neck cancer patients undergoing chemo-radiotherapy: clinical practical recommendations,” Critical Reviews in Oncology/Hematology, vol. 99, pp. 100–106, 2016.

J. B. Epstein and K. H. Stewart, “Radiation therapy and pain in patients with head and neck cancer,” European Journal of Cancer Part B: Oral Oncology, vol. 29, no. 3, pp. 191–199, 1993.

M. Costigan, J. Scholz, and C. J. Woolf, “Neuropathic pain: a maladaptive response of the nervous system to damage,” Annual Review of Neuroscience, vol. 32, no. 1, pp. 1–32, 2009.

H. Kehlet, T. S. Jensen, and C. J. Woolf, “Persistent postsurgical pain: risk factors and prevention,” The Lancet, vol. 367, no. 9522, pp. 1618–1625, 2006.

C. A. Christianson, M. Corr, G. S. Firestein, A. Mobargha, T. L. Yaksh, and C. I. Svensson, “Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis,” Pain, vol. 151, no. 2, pp. 394–403, 2010.

A. Feizerfan and G. Sheh, “Transition from acute to chronic pain,” Continuing Education in Anaesthesia Critical Care & Pain, vol. 15, no. 2, pp. 98–102, 2015.

P.-Y. Kuo and J. E. Williams, “Pain control in head and neck cancer,” in Head and Neck Cancer, IntechOpen, London, UK, 2012, https://www.intechopen.com/books/head-and-neck-cancer/pain-and-symptom-control-in-head-and-neck-cancer.

P. Srivastava, P. A. Kingsley, H. Srivastava, J. Sachdeva, and P. Kaur, “Persistent post-radiotherapy pain and locoregional recurrence in head and neck cancer-is there a hidden link?” Korean Journal of Pain, vol. 28, no. 2, pp. 116–121, 2015.

R. Fink, “Pain assessment: the cornerstone to optimal pain management,” Baylor University Medical Center Proceedings, vol. 13, no. 3, pp. 236–239, 2000.

V. Ranpura, S. Agrawal, P. Chokshi et al., “Improving documentation of pain management at MedStar Washington cancer Institute,” Journal of Oncology Practice, vol. 11, no. 2, pp. 155–157, 2015.

X. Liu, X.-L. Gao, X.-H. Liang, and Y.-L. Tang, “The etiologic spectrum of head and neck squamous cell carcinoma in young patients,” Oncotarget, vol. 7, no. 40, 2016.

M. H. Larizadeh, M. A. Damghani, and M. Shabani, “Epidemiological characteristics of head and neck cancers in southeast of Iran,” Iranian Journal of Cancer Prevention, vol. 7, no. 2, pp. 80–86, 2014.

The Demographic Statistical Atlas of the United States-Statistical Atlas, https://statisticalatlas.com/state/Illinois/Overview.

E. M. Rettig and G. D’Souza, “Epidemiology of head and neck cancer,” Surgical Oncology Clinics of North America, vol. 24, no. 3, pp. 379–396, 2015.

F. Silvestri, B. Bussani, G. Stanta, C. Cosatti, and F. Ferlito, “Supraglottic versus glottic laryngeal cancer: epidemiological and pathological aspects,” ORL, vol. 54, no. 1, pp. 43–48, 1992.

J. B. Epstein, D. J. Wilkie, D. J. Fischer, Y.-O. Kim, and D. Villines, “Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy,” Head & Neck Oncology, vol. 1, no. 1, p. 26, 2009.

V. B. Ad, G. Weinstein, P. R. Dutta et al., “Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy,” Cancer, vol. 116, no. 17, pp. 4206–4213, 2010.

T. Gomes, D. N. Juurlink, T. Antoniou, M. M. Mamdani, J. M. Paterson, and W. van den Brink, “Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study,” PLoS Medicine, vol. 14, no. 10, Article ID e1002396, 2017.

B. A. Murphy, J. L. Beaumont, J. Isitt et al., “Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy,” Journal of Pain and Symptom Management, vol. 38, no. 4, pp. 522–532, 2009.

I. Vistad, M. Cvancarova, G. B. Kristensen et al., “A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer,” Journal of Cancer Survivorship, vol. 5, no. 2, pp. 208–216, 2011.

E. L. Poleshuck, J. Katz, C. H. Andrus et al., “Risk factors for chronic pain following breast cancer surgery: a prospective study,” Journal of Pain, vol. 7, no. 9, pp. 626–634, 2006.

V. Peuckmann, O. Ekholm, N. K. Rasmussen et al., “Chronic pain and other sequelae in long-term breast cancer survivors: nationwide survey in Denmark,” European Journal of Pain, vol. 13, no. 5, pp. 478–485, 2009.

J. S. Cooper, K. Fu, J. Marks, and S. Silverman, “Late effects of radiation therapy in the head and neck region,” International Journal of Radiation Oncology∗Biology∗Physics, vol. 31, no. 5, pp. 1141–1164, 1995.

R. K. Portenoy and P. Lesage, “Management of cancer pain,” The Lancet, vol. 353, no. 9165, pp. 1695–1700, 1999.

C. M. Glastonbury, E. E. Parker, and J. K. Hoang, “The postradiation neck: evaluating response to treatment and recognizing complications,” American Journal of Roentgenology, vol. 195, no. 2, 2010.

J. Deng, S. H. Ridner, M. S. Dietrich et al., “Prevalence of secondary lymphedema in patients with head and neck cancer,” Journal of Pain and Symptom Management, vol. 43, no. 2, pp. 244–252, 2012.

S. Delanian and J.-L. Lefaix, “The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway,” Radiotherapy and Oncology, vol. 73, no. 2, pp. 119–131, 2004.

C.-A. Bach, I. Wagner, X. Lachiver, B. Baujat, and F. Chabolle, “Botulinum toxin in the treatment of post-radiosurgical neck contracture in head and neck cancer: a novel approach,” European Annals of Otorhinolaryngology, Head and Neck Diseases, vol. 129, no. 1, pp. 6–10, 2012.

D. J. V. Daele, E. M. Finnegan, R. L. Rodnitzky et al., “Spasm after radiotherapy: management with botulinum toxin a injection,” Archives of Otolaryngology–Head & Neck Surgery, vol. 128, no. 8, pp. 956–959, 2002.